Inclusion Criteria
* Patient/legally authorized representative has signed the Informed Consent Form.
* Ability to comply with the study protocol, in the investigator's judgment.
* Patients 18 to 80 years of age with an ICH had occurred within 24 hours before admission.
* Spontaneous supratentorial (basal ganglia, thalamus, lobar) ICH ≥30 mL measured utilizing the ABC/2 method.
* Subjects with a GCS score of 5-14.
* NIHSS ≥6.
* Stability CT scan done at least 6 hours after baseline CT showing clot stability (growth \<5 mL as measured by ABC/2 method). If the hematoma volume measured on the stability CT scan increases by 5 mL or more, a second stability CT scan will be performed 12 hours later.
* Sustained systolic blood pressure (SBP) \<180 mm Hg for six hours recorded closest to the time of drug administration.
* Symptoms must be present less than 24 hours prior to baseline CT scan.
* Baseline Rankin score of 0 or 1.
Exclusion Criteria
* Presence of infratentorial parenchymal bleeding.
* Presence of a hemorrhage extending to the midbrain.
* An unknown time of onset or the symptoms onset more than 24 hours prior to admission.
* Pregnancy.
* Inability to obtain written informed consent from subject or legal representative.
* Sustained SBP \>180 mm Hg for six hours recorded closest to the time of drug administration.
* Age \<18 and \>80 years.
* Radiological evidence of arterio-venous malformation, aneurysm, amyloid angiopathy, Moyamoya disease, hemorrhagic conversion of an ischemic stroke, recurrent hemorrhage in the same location within the past 365 year or unstable mass as a source for the ICH.
* Evidence of coagulopathy (international normalized ratio \>1.3; platelet count \<100 ,000 or platelet dysfunction P2Y-12 \>250) or known clotting disorder.
* Bilateral fixed, dilated pupils indicating irreversible impaired brain stem function with GCS ≤4.
* Patients with severe ICH and IVH who require an external ventricular drain (EVD) placement for cerebrospinal fluid (CSF) diversion or separate intraventricular thrombolysis.
* Inability to maintain INR less than 1.3.
* Use of anticoagulants prior to symptom onset and subjects requiring long-term anticoagulants (the reversal is permitted if the patient can tolerate the short-term risk of reversal).
* Use of Dabigatran, Apixaban, and/or Rivaroxaban (or a similar medication from the similar medication class) prior to symptom onset.
* Internal bleeding (GI, renal, respiratory etc).
* Mechanical heart valve (Bioprosthetic heart valve is permitted).
* Known risk for embolization, including history of left heart thrombus, mitral stenosis with atrial fibrillation, acute pericarditis, or subacute bacterial endocarditis (atrial fibrillation without mitral stenosis is permitted).
* Allergy or sensitivity to TNKase.
* Participation in a concurrent clinical trial.
* Serious illness (advanced stage which can interfere with the outcome).
* The patient is unstable and would not benefit from a surgical intervention.
* GCS score of 3-4 and 15 (to ensure patient safety and study feasibility).
* Historical mRS score of 2-6 (at admission).
* Symptomatic tract hemorrhage or a tract hemorrhage more than 5 mm.
